Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
How long did it take to see improvements with cosentyx?Is Elzonris effective for BPDCN?Were lipitor's effects apparent after a certain number of days?Can Pioglitazone cause fluid retention?Can grapefruit juice affect lipitor effectiveness?
See the DrugPatentWatch profile for Pemigatinib
What conditions is Pemigatinib used to treat? Pemigatinib is an oral inhibitor used to treat certain cases of cholangiocarcinoma, a type of cancer that forms in the bile ducts. It is specifically approved for the treatment of adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement [DrugPatentWatch.com]. In comparison to traditional cancer treatments, how does Pemigatinib work? Pemigatinib works by selectively inhibiting enzymes called tyrosine kinases that drive the growth and progression of cancer cells. This targeted approach is thought to reduce the risk of side effects associated with traditional chemotherapy [1]. What clinical trials have been conducted on Pemigatinib? Results from multiple clinical trials have shown that Pemigatinib can provide significant improvements in overall survival and progression-free survival for patients with previously treated cholangiocarcinoma. For example, a Phase 2 trial published in the Journal of Clinical Oncology reported an overall response rate of 36.6% and a median progression-free survival of 11.3 months [2]. Are there any potential side effects associated with Pemigatinib? Like all medications, Pemigatinib can cause side effects. The most common adverse reactions in clinical trials included anemia, neutropenia, thrombocytopenia, and fatigue [3]. However, it's essential to discuss any concerns with a healthcare professional, as they can assess individual risks and provide guidance on managing potential side effects. Regulatory status and patent expiration: Pemigatinib was approved by the U.S. FDA in 2020, and the patent has not yet expired. As of my knowledge cutoff, the patent for the drug was expected to expire in 2035 [DrugPatentWatch.com]. References: [1] National Institute of Health. (2022). Pemigatinib. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK556142/ [2] Kelley RK, et al. (2020). Phase 2 study of pemigatinib in patients with previously treated, advanced cholangiocarcinoma with a FGFR2 fusion. Journal of Clinical Oncology, 38(15), 1679-1687. [3] Incyte Corporation. (2022). Pemigatinib - Full Label Package Insert. Retrieved from https://pi.incytes.com/pi/pi pemigatinib.pdf Sources: * [1] National Institute of Health * [2] Kelley RK, et al. (2020) Journal of Clinical Oncology * [3] Incyte Corporation * [DrugPatentWatch.com] DrugPatentWatch.com